pharmaphorum

AUGUST 17, 2020

N o one industry is ever quite like another, but there are some valuable lessons for pharma marketing from examining how the financial sector uses technology, builds brands on social channels and approaches digital content. Nevertheless, the advent of COVID-19 is forcing pharma, and many other sectors, to make some radical changes.

Communication 87

Communication Insurance Packaging Pharmaceutical Companies 87

Pharmaceutical Technology

DECEMBER 5, 2022

Cannabinoid receptors are a popular therapeutic target for cannabinoid-based drugs in the treatment of pain, neurological disorders and inflammation, according to GlobalData’s Pharma Intelligence Centre Drugs database. This is closely followed by CB2 receptors in second place.

Controlled Substances 98

Controlled Substances Compounding Immunization 98

pharmaphorum

SEPTEMBER 15, 2020

Companies like prescription glasses firm Warby Parker, shoe brand Rothy’s and tele-dentistry’s SmileDirectClub have grown up in today’s digitally native environment and can offer some key pointers for pharma. As part of this, a number of big pharma companies are also racing to develop a safe and effective vaccine for the coronavirus.

Communication 114

Communication Documentation Labelling Vaccines 114

pharmaphorum

AUGUST 21, 2022

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. Auvelity is the first drug Axsome has taken through to regulatory approval, but could be the first of a string of new products for the company, according to Tabuteau.

FDA 96

FDA Labelling 96

pharmaphorum

MAY 17, 2021

Apellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal hemoglobinuria (PNH) – with a label that will allow it to challenge Alexion’s established therapies directly. . billion and $1.1

FDA 52

FDA Labelling Vaccines 52

pharmaphorum

JUNE 2, 2022

This is why the action by the US in 1983 and subsequently the European Commission Regulation No. 141/2000 (the Orphan Regulation), that both acted to encourage development in the area, are regarded as crucial for changing the landscape in rare disease R&D. It is estimated that between 3.5 The price is right. Raising questions.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Viseven

SEPTEMBER 14, 2023

The pharma sector now reconsiders its procurement process for improved efficiency, resilience, and cost optimization. Discover the innovative approaches that pharma brands employ to effectively address challenges and drive progress. Climate change is another factor, potentially disrupting supplies and contributing to hefty price tags.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Pharmacy Procurement 52